• Source : Press Release
  • Date : 2017-02-08
  • Event type : Pre Clinical

Spotlight Innovation Engages Top-Tier Contract Research Organization to Conduct Preclinical Studies of STL-182

URBANDALE, Iowa, Feb. 8, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that it has engaged a top-tier contract research organization (CRO) to conduct additional preclinical mouse studies of STL-182, the Company's proprietary small molecule product candidate for the treatment of spinal muscular atrophy (SMA). Synthesis and early preclinical testing of STL-182 was accomplished through a research collaboration between Professors Elliot Androphy of Indiana University School of Medicine and Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital. Professor Androphy and Professor Hodgetts are members of Spotlight Innovation's Scientific Advisory Board. Spinal Muscular Atrophy affects between 1 in 6,000 and 1 in 10,000 newborns. Approximately 1 in 40 to 1 in 50 adults have only a single intact spinal motor neuron 1 (SMN1) gene, which encodes a protein (SMN) required for proper neuromuscular function. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two. Even in SMA patients, low levels of functional SMN protein are produced by an SMN1-related gene called SMN2. One therapeutic strategy to treat SMA is to increase levels of functional SMN protein encoded by SMN2. In mouse models of SMA, STL-182 may restore neuromuscular function by stabilizing endogenous SMN protein.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit or follow us on